Palmetto Peptides Glow Stack Full Research Guide
Palmetto Peptides Glow Stack Full Research Guide
Last Updated: April 3, 2026 Author: Palmetto Peptides Research Team
Research Use Only Disclaimer: All compounds discussed in this guide — GHK-Cu, BPC-157, and TB-500 — are research peptides intended exclusively for in vitro and preclinical laboratory research. They are not approved by the FDA for human or veterinary use, are not dietary supplements, and are not intended to diagnose, treat, cure, or prevent any disease or condition. This guide is educational in nature and draws exclusively from peer-reviewed preclinical and in vitro literature. Palmetto Peptides sells exclusively to licensed researchers and institutions for legitimate scientific study.
What Is the Glow Stack?
The Glow Stack is a preclinical research combination consisting of three peptides: GHK-Cu (glycyl-histidyl-lysine copper), BPC-157 (body protection compound 157), and TB-500 (thymosin beta-4 synthetic analog). Each compound has its own substantial body of peer-reviewed preclinical research. Together, they represent one of the most mechanistically layered peptide combinations studied in the context of tissue regeneration, extracellular matrix (ECM) remodeling, and anti-inflammatory activity in laboratory models.
The name "Glow Stack" reflects the preponderance of research on these three compounds in skin, connective tissue, and wound healing models — areas where the interplay between ECM architecture, vascular development, and inflammation resolution is most clearly documented in the preclinical literature.
This guide covers every major aspect of the Glow Stack research combination: what each peptide does, how they interact, what the preclinical evidence shows, and what researchers need to know about sourcing, storage, and study design. Each section links to deeper supporting articles for investigators who need more detail on a specific topic.
The Three Compounds at a Glance
Before diving into mechanisms, here is a quick-reference summary of each Glow Stack component:
| Compound | Type | Molecular Weight | Primary Research Domains |
|---|---|---|---|
| GHK-Cu | Naturally occurring tripeptide + copper | ~403 g/mol (complex) | ECM remodeling, antioxidant, anti-inflammatory, hair follicle |
| BPC-157 | Synthetic 15-amino acid peptide | 1419.5 g/mol | Vascular repair, anti-inflammatory, GI/tendon healing, angiogenesis |
| TB-500 | Thymosin beta-4 analog (17 aa) | ~2025 g/mol | Actin dynamics, cell migration, angiogenesis, anti-apoptotic |
Each compound is structurally and mechanistically distinct. Their combination is not redundant — it is complementary, with each peptide operating through different primary pathways while converging on shared outcomes in tissue repair and remodeling models.
GHK-Cu: The ECM Architect
What GHK-Cu Is
GHK-Cu is a naturally occurring copper-binding tripeptide first identified in human plasma by Pickart in the 1970s. The sequence — glycine, histidine, lysine — chelates copper(II) ions through the histidine imidazole ring, forming a stable complex that delivers bioavailable copper to tissue while simultaneously engaging peptide-specific biological pathways.
It is not simply a copper delivery vehicle. The peptide portion of GHK-Cu engages integrin receptors, modulates transcription factor activity, and has been linked through genomic analyses to regulatory networks controlling upward of 4,000 genes — including genes governing ECM synthesis, inflammation, oxidative stress, cell survival, and DNA repair (Pickart & Margolina, 2018).
Primary Mechanisms in Preclinical Models
Collagen regulation: GHK-Cu upregulates COL1A1 and COL1A2 (the genes encoding collagen type I alpha chains) in fibroblast cultures. Critically, it supports organized basket-weave collagen architecture rather than the parallel scar-type collagen seen in basic wound healing responses (Maquart et al., 1988).
Lysyl oxidase (LOX) activation: GHK-Cu's copper delivery supports LOX, the copper-dependent enzyme responsible for crosslinking collagen and elastin into load-bearing extracellular networks. This crosslinking activity is what gives mature, remodeled tissue its tensile strength and is what distinguishes GHK-Cu's long-term remodeling contributions from shorter-acting wound healing signals.
Antioxidant enzyme induction: GHK-Cu upregulates SOD1 (superoxide dismutase), catalase, and glutathione peroxidase in cell culture models — effects that exceed what copper delivery alone produces and indicate peptide-specific gene regulatory activity (Pickart et al., 2015).
NF-kB suppression: GHK-Cu inhibits canonical NF-kB pathway activation, reducing transcription of pro-inflammatory cytokines including TNF-alpha, IL-1beta, and IL-6 in LPS-stimulated macrophage and fibroblast models.
VEGF and angiogenic signaling: GHK-Cu upregulates VEGF in fibroblast and keratinocyte models, supporting the vascular component of tissue repair alongside BPC-157 and TB-500.
For a full mechanistic breakdown, see GHK-Cu Research Peptide Mechanisms.
BPC-157: The Vascular and Repair Architect
What BPC-157 Is
BPC-157 is a synthetic 15-amino acid peptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a naturally occurring protein found in gastric juice. It does not occur in this form in nature — it is a research-designed stable fragment with a substantial and growing preclinical evidence base spanning wound healing, tendon repair, angiogenesis, and gastrointestinal tissue models.
Primary Mechanisms in Preclinical Models
VEGF upregulation and angiogenesis: BPC-157 is one of the most studied peptides for vascular endothelial growth factor stimulation in preclinical models. Rat tendon, muscle, and wound healing studies consistently show increased microvessel density in BPC-157-treated tissue relative to controls (Sikiric et al., 2018).
Nitric oxide modulation: BPC-157 influences nitric oxide (NO) signaling through both eNOS-dependent and eNOS-independent pathways. This contributes to vasodilation, blood flow regulation, and cytoprotection in preclinical models.
FAK-paxillin pathway: Research by Sikiric's group has documented BPC-157's engagement of focal adhesion kinase (FAK) and paxillin signaling — pathways governing cell adhesion, migration, and cytoskeletal organization relevant to wound healing and angiogenesis (Chang et al., 2011).
Anti-inflammatory signaling: BPC-157 reduces systemic and local inflammatory markers in rodent models of acute and chronic injury, working through pathways partially distinct from GHK-Cu's NF-kB-centered mechanism.
Tendon and ligament models: Among all the Glow Stack components, BPC-157 has the most published data in musculoskeletal models — specifically Achilles tendon transection and ligament repair models in rodents, where treated animals show accelerated histological healing and improved functional recovery versus controls.
TB-500: The Migration and Actin Architect
What TB-500 Is
TB-500 is a synthetic analog of thymosin beta-4 (Tβ4), a ubiquitous intracellular protein involved in actin monomer sequestration and cytoskeletal dynamics. Tβ4 is found in virtually all mammalian cells and plays a foundational role in cell motility, wound repair, and developmental biology. TB-500 replicates the bioactive region of Tβ4 (typically the LKKTETQ actin-binding domain) in a stable, water-soluble research compound.
Primary Mechanisms in Preclinical Models
Actin dynamics and cell migration: TB-500 sequesters G-actin (monomeric actin), modulating the ratio of free to polymerized actin in cells. This shifts cells toward a migratory phenotype, accelerating the movement of keratinocytes, fibroblasts, and endothelial cells — all key cell types in wound repair — toward sites of injury (Goldstein et al., 2012).
Angiogenesis: TB-500 promotes endothelial cell migration and tube formation in vitro, and increases microvessel formation in vivo. This angiogenic activity works synergistically with BPC-157's VEGF stimulation in wound models.
Anti-apoptotic signaling: Tβ4 and TB-500 reduce apoptosis in injured cells through Akt (protein kinase B) pathway activation, increasing cell survival in oxidatively stressed tissue.
Anti-inflammatory effects: TB-500 reduces macrophage-mediated inflammatory signaling in wound models, contributing to the anti-inflammatory coverage shared across all three Glow Stack components.
Cardiac and skeletal muscle models: TB-500 has a notable evidence base in cardiac repair models — myocardial infarction studies in rodents have shown reduced infarct size and improved contractile function with Tβ4/TB-500 administration, though this is far outside the typical regenerative skin/connective tissue domain of the Glow Stack.
How the Three Peptides Work Together: Mechanistic Synergy
This is where the Glow Stack's research interest lies. Each peptide works on a different structural and signaling layer of tissue repair. When combined in preclinical models, the mechanistic coverage is broader than any single compound.
The Division of Labor
Think of tissue repair as a construction project with three phases: demolition and cleanup (inflammation resolution), foundation and infrastructure (angiogenesis and cell migration), and finishing work (ECM remodeling and scar prevention). The Glow Stack addresses all three simultaneously:
| Repair Phase | Primary Glow Stack Contributor | Supporting Role |
|---|---|---|
| Inflammation resolution | GHK-Cu (NF-kB, cytokine suppression) | BPC-157, TB-500 (anti-inflammatory) |
| Angiogenesis | BPC-157 (VEGF, FAK, NO) | TB-500 (endothelial migration), GHK-Cu (VEGF) |
| Cell migration | TB-500 (actin dynamics, G-actin sequestration) | BPC-157 (FAK-paxillin) |
| ECM synthesis | GHK-Cu (collagen, fibronectin, proteoglycans) | BPC-157 (collagen in tendon models) |
| ECM maturation/crosslinking | GHK-Cu (LOX activation) | — |
| Anti-scarring | GHK-Cu (TGF-beta3 shift, collagen architecture) | TB-500 (anti-apoptotic) |
| Antioxidant coverage | GHK-Cu (SOD1, catalase, GPx) | BPC-157 (NO modulation) |
VEGF Amplification: Where BPC-157 and GHK-Cu Overlap Productively
Both BPC-157 and GHK-Cu independently upregulate VEGF in preclinical models. Rather than being redundant, this parallel pathway engagement is thought to amplify angiogenic signaling through different regulatory nodes — BPC-157 via FAK/NO/eNOS, GHK-Cu through fibroblast-mediated paracrine VEGF secretion. TB-500 then adds endothelial cell migratory capacity, turning the amplified VEGF signal into actual tube formation and vessel development.
Actin-Integrin Complementarity: Where TB-500 and GHK-Cu Interact
TB-500's actin sequestration promotes cellular migration. GHK-Cu's integrin engagement promotes cellular adhesion and ECM interaction. In combination, this creates a coordinated repair dynamic: TB-500 gets cells moving, GHK-Cu ensures they adhere correctly and remodel the matrix they encounter.
Antioxidant Protective Layer
Tissue repair generates reactive oxygen species (ROS) as a byproduct of the inflammatory and proliferative phases. GHK-Cu's robust antioxidant enzyme induction — SOD1, catalase, glutathione peroxidase — provides a protective layer that may reduce oxidative damage to the new tissue being laid down. This is a role neither BPC-157 nor TB-500 replicates with the same mechanistic depth.
For a full mechanistic breakdown of stack synergy, see GHK-Cu + BPC-157 + TB-500 Synergy in Regenerative Research.
Glow Stack vs. Wolverine Stack: How They Differ
Researchers and research teams sometimes ask how the Glow Stack compares to the Wolverine Stack — a popular two-peptide combination of BPC-157 and TB-500.
The short answer: the Wolverine Stack is the Glow Stack minus GHK-Cu. Adding GHK-Cu changes the combination's emphasis toward skin and connective tissue ECM quality, antioxidant coverage, and long-term remodeling outcomes.
| Dimension | Wolverine Stack (BPC-157 + TB-500) | Glow Stack (GHK-Cu + BPC-157 + TB-500) |
|---|---|---|
| ECM architecture | Limited | Extensive (GHK-Cu's primary contribution) |
| LOX-driven collagen crosslinking | Absent | Present |
| Antioxidant enzyme induction | Minimal | Robust (SOD1, catalase, GPx) |
| Anti-scarring activity | Minimal | Documented (TGF-beta3 shift) |
| Skin/follicular research data | Limited | Extensive |
| Acute vascular repair | Strong | Strong |
| Musculoskeletal models | Strong | Moderate (ECM benefits apply) |
| Genomic regulatory breadth | Moderate | Very broad (GHK-Cu adds 4,000+ gene network) |
For researchers whose primary interest is acute vascular repair or musculoskeletal healing, the Wolverine Stack may be sufficient. For researchers focused on skin quality, ECM architecture, hair follicle biology, or long-duration remodeling outcomes, the Glow Stack's addition of GHK-Cu is mechanistically justified by the preclinical literature.
See the full comparison: Glow Stack vs. Wolverine Stack: Research Peptide Comparison.
Preclinical Evidence Summary by Research Domain
Wound Healing Models
Rodent excisional and incisional wound models have been used to study all three Glow Stack components individually. Key findings across the literature:
- GHK-Cu: Increased wound closure rate, improved collagen organization, reduced scar formation, and increased dermal fibroblast density in 14–28 day murine models
- BPC-157: Accelerated wound closure with increased microvessel density and reduced inflammatory infiltrate in rat skin and subcutaneous models
- TB-500: Enhanced keratinocyte migration and re-epithelialization in corneal and skin wound models; reduced healing time in rodent dermal excision studies
These findings converge across overlapping endpoints, suggesting the combination would produce additive or synergistic outcomes — though direct head-to-head combination studies remain limited in the published literature.
For wound healing model specifics, see Preclinical Wound Healing Research: GHK-Cu and the Glow Stack.
Skin Quality and Anti-Aging Research Models
GHK-Cu has the most developed preclinical literature in this domain. Aged murine skin models show increased dermal thickness, improved collagen fiber organization, and epidermal stratification improvements after 4–8 weeks of repeated GHK-Cu administration. BPC-157's VEGF stimulation contributes capillary density improvements relevant to nutrient delivery in aged tissue. TB-500's anti-apoptotic Akt signaling may support dermal cell survival in oxidatively stressed aged tissue.
See Long-Term Preclinical Implications of GHK-Cu in Tissue Regeneration Research for extended-duration model data.
Hair Follicle Research Models
GHK-Cu has the strongest preclinical evidence in hair follicle biology among the three compounds. Dermal papilla (DP) cell proliferation, VEGF/KGF/HGF upregulation in follicular cells, and Wnt/beta-catenin pathway modulation (relevant to anagen induction) have all been documented in laboratory models. BPC-157's vascular effects are relevant to perifollicluar capillary density. TB-500's actin dynamics may support DP cell migration during follicle cycling.
Full follicular research coverage: GHK-Cu Hair Follicle and Dermal Research in Preclinical Models.
Anti-Inflammatory Research Models
All three compounds demonstrate anti-inflammatory activity in preclinical models, operating through distinct but complementary pathways:
- GHK-Cu: NF-kB suppression, cytokine downregulation (TNF-alpha, IL-1beta, IL-6), antioxidant-mediated ROS-NF-kB feedback interruption
- BPC-157: Systemic and local inflammatory marker reduction, NO-mediated vascular protection
- TB-500: Macrophage modulation, Akt-mediated cell survival reducing secondary inflammatory damage
See GHK-Cu Antioxidant and Anti-Inflammatory Properties in Preclinical Models and GHK-Cu Anti-Inflammatory Activity in Animal Models for deeper coverage.
Collagen and ECM Research
GHK-Cu is the primary ECM contributor in the Glow Stack. The collagen synthesis literature for GHK-Cu is among the most replicated in the copper peptide field, with consistent findings across fibroblast cultures, animal wound models, and aged skin models. BPC-157 has documented collagen effects in tendon models specifically. TB-500 contributes through ECM-interacting cell migration support.
See GHK-Cu Collagen Synthesis and Skin Regeneration in Preclinical Models for the full collagen research review.
Sourcing the Glow Stack: What Researchers Need to Know
Why Purity Is Non-Negotiable in Peptide Research
The reproducibility of any preclinical peptide study depends on the purity and identity of the compounds used. A peptide sold as "95% pure" with no third-party HPLC documentation could contain synthesis byproducts, truncated sequences, or residual solvents that introduce confounding variables into experimental results.
For the Glow Stack specifically:
- GHK-Cu can be adulterated with free copper salts or shorter degradation fragments that produce different biological effects
- BPC-157 is a 15-amino acid sequence; truncated or scrambled analogs will have different receptor binding profiles
- TB-500 peptide synthesis complexity increases the risk of aggregation artifacts or incorrect sequence assembly
Researchers should require third-party HPLC chromatography and mass spectrometry confirmation for each compound before use in any protocol.
Purity Thresholds by Peptide
| Peptide | Minimum Research-Grade Purity | Preferred |
|---|---|---|
| GHK-Cu | ≥ 95% | ≥ 98% |
| BPC-157 | ≥ 98% | ≥ 99% |
| TB-500 | ≥ 95% | ≥ 98% |
Individual Peptides vs. Pre-Formulated Blends
Researchers have the option of sourcing each compound separately and combining them in-house, or purchasing pre-formulated Glow Stack blends from a supplier. Each approach has trade-offs:
Individual sourcing:
- Full control over dose ratios
- Easier to isolate individual compound effects with proper control arms
- Flexibility to adjust concentrations between study phases
Pre-formulated blends:
- Convenience for laboratories without compounding capacity
- Require verification that each component meets purity standards independently
- Ratio fixed at formulation — less flexibility
For full sourcing guidance, see Sourcing GHK-Cu, BPC-157, and TB-500: Research Blend Best Practices. For purity testing specifics, see GHK-Cu Peptide Purity Testing and Quality Assurance.
Palmetto Peptides supplies individually third-party-tested GHK-Cu, BPC-157, and TB-500 with certificate of analysis documentation for each batch.
Storage and Reconstitution: Handling the Glow Stack in the Lab
Peptides are environmentally sensitive compounds. Improper storage or reconstitution is one of the most common sources of data variability in preclinical peptide research.
Storage at a Glance
| Compound | Lyophilized (Dry) Storage | Reconstituted Storage |
|---|---|---|
| GHK-Cu | Room temp (short); –20°C (long) | 2–8°C up to 7 days; –20°C for longer |
| BPC-157 | –20°C, desiccated, light-protected | 2–8°C up to 5 days; do not refreeze |
| TB-500 | –20°C, desiccated | 2–8°C up to 7 days; aliquot before freezing |
Reconstitution Basics
All three peptides are typically supplied lyophilized (freeze-dried powder). Reconstitution guidelines:
- Allow vials to reach room temperature before opening — prevents moisture condensation
- Add solvent (bacteriostatic water for most applications; sterile water for GHK-Cu) slowly down the vial wall — do not inject directly into the powder
- Roll gently to mix — do not vortex, which can cause peptide aggregation
- Inspect for clarity — cloudy solution indicates incomplete dissolution or aggregation
- For cell culture applications, filter through 0.22 μm syringe filter after reconstitution
GHK-Cu is slightly more pH-sensitive than BPC-157 or TB-500; maintaining a neutral to mildly acidic reconstitution pH (6.5–7.0) supports stability.
Full protocol detail: GHK-Cu, BPC-157, and TB-500 Storage, Reconstitution, and Handling Guide.
GHK-Cu vs. Other Copper Peptides: Why GHK-Cu Is the Right Choice for the Glow Stack
Researchers new to copper peptide research sometimes ask whether GHK-Cu can be substituted with related compounds like AHK-Cu or Pal-GHK (palmitoyl tripeptide-1). The short answer is no — and the distinction matters for experimental validity.
AHK-Cu shares some mechanisms with GHK-Cu but has a much smaller evidence base and lacks the gene regulatory characterization, NF-kB data, and hair follicle research published for GHK-Cu.
Pal-GHK (palmitoyl tripeptide-1 / Matrixyl) shares the GHK sequence but does not chelate copper. It cannot activate LOX, induce antioxidant enzymes via copper delivery, or replicate GHK-Cu's full mechanistic profile.
Simple copper salts (copper gluconate, CuCl₂) deliver copper but engage none of the peptide-specific receptor and gene regulatory pathways that distinguish GHK-Cu in the literature.
GHK-Cu is the only copper peptide with the combination of copper delivery, integrin engagement, NF-kB modulation, broad gene regulation, LOX activation, and extensive published preclinical characterization required for valid Glow Stack research.
Full comparative review: GHK-Cu vs. Other Copper Peptides: Preclinical Literature Review.
Study Design Considerations for Glow Stack Research
Investigators planning Glow Stack protocols should account for several design-level considerations that are specific to multi-peptide combination studies:
Duration: GHK-Cu's most distinctive contributions — LOX-driven collagen crosslinking, ECM organization, TGF-beta3 anti-scarring shift — emerge most clearly after 3+ weeks of repeated administration. Short (7-day) protocols will capture acute-phase BPC-157 and TB-500 effects more prominently than GHK-Cu's remodeling contributions. Design for the endpoint you need.
Control arms: At minimum, include: vehicle control, each compound individually, and the full stack. This allows attribution of effects to specific components and detection of true synergy versus additivity.
Endpoint selection: Standard wound closure metrics (planimetry, H&E staining) are insufficient for capturing the Glow Stack's most distinctive outputs. Add: collagen crosslink quantification (pyridinoline HPLC), tensile strength testing, multi-timepoint gene expression panels (ECM, antioxidant, inflammatory markers), immunohistochemistry for collagen I/III ratio, and capillary density quantification.
Dose: Published ranges vary widely across the literature. Researchers should establish dose-response curves in pilot studies rather than assuming published single-dose findings transfer directly to their model system.
Route of administration: Subcutaneous, intradermal, topical, and intraperitoneal routes have all been used in the published literature, each with different pharmacokinetic profiles. Route selection should be driven by the research question and the tissue model, not convenience alone.
Supporting Research Articles
- Glow Stack Synergistic Effects
- GHK-Cu Mechanism of Action
- GHK-Cu Wound Healing Research
- GHK-Cu Collagen and Skin Research
- GHK-Cu Hair Follicle Research
- GHK-Cu Antioxidant Research
- GHK-Cu Anti-Inflammatory Research
- GHK-Cu Long-Term Tissue Research
- GHK-Cu vs Other Copper Peptides
- Glow Stack vs Wolverine Stack
- Glow Stack Storage and Reconstitution
- Sourcing Glow Stack Peptides
- GHK-Cu Purity Testing
Frequently Asked Questions
Full Supporting Article Library
This pillar page is the hub of the Palmetto Peptides Glow Stack research content cluster. The supporting articles below go deeper on specific topics. Use them as a research library — each article is self-contained but links back to this guide and to related articles in the cluster.
| Topic | Article |
|---|---|
| Mechanisms of action | GHK-Cu Research Peptide Mechanisms of Action |
| Collagen and skin regeneration | GHK-Cu Collagen Synthesis and Skin Regeneration in Preclinical Models |
| Antioxidant and anti-inflammatory (in vitro) | GHK-Cu Antioxidant and Anti-Inflammatory Properties in Preclinical Models |
| Stack synergy deep dive | GHK-Cu + BPC-157 + TB-500 Synergy: Glow Stack Regenerative Research |
| Wound healing models | Preclinical Wound Healing Research: GHK-Cu and the Glow Stack |
| Hair follicle and dermal research | GHK-Cu Hair Follicle and Dermal Research in Preclinical Models |
| Glow Stack vs. Wolverine Stack | Glow Stack vs. Wolverine Stack: Research Peptide Comparison |
| Purity testing and QA | GHK-Cu Peptide Purity Testing and Quality Assurance |
| Sourcing best practices | Sourcing GHK-Cu, BPC-157, and TB-500: Research Blend Best Practices |
| Storage and reconstitution | GHK-Cu, BPC-157, and TB-500 Storage, Reconstitution, and Handling Guide |
| Anti-inflammatory animal models | GHK-Cu Anti-Inflammatory Activity in Animal Models and In Vitro Systems |
| Long-term preclinical tissue regeneration | Long-Term Preclinical Implications of GHK-Cu in Tissue Regeneration Research |
| GHK-Cu vs. other copper peptides | GHK-Cu vs. Other Copper Peptides: Preclinical Literature Review |
Summary
The Glow Stack — GHK-Cu, BPC-157, and TB-500 — represents a mechanistically layered research combination whose preclinical evidence base spans ECM remodeling, angiogenesis, cell migration, inflammation resolution, antioxidant defense, and anti-scarring activity. No single compound produces all of these effects. The stack's value lies in the complementarity: BPC-157 and TB-500 drive the acute vascular and migratory response; GHK-Cu builds and organizes the matrix those cells populate and sustains antioxidant coverage throughout the repair process.
For researchers building multi-week tissue regeneration protocols, the Glow Stack offers the most mechanistically comprehensive copper-peptide-inclusive combination currently documented in the preclinical literature. Proper sourcing (third-party tested, HPLC and MS confirmed), correct storage (lyophilized at –20°C), and appropriate study design (extended duration, matched controls, ECM-quality endpoints) are prerequisites for generating reproducible, publication-quality data.
Palmetto Peptides provides individually tested, certificate-of-analysis-documented GHK-Cu, BPC-157, and TB-500 for qualifying laboratory researchers.
References
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. doi:10.3390/ijms19071987
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International. 2015;2015:648108. doi:10.1155/2015/648108
- Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters. 1988;238(2):343–346.
- Sikiric P, Hahm KB, Blagaic AB, et al. Stable gastric pentadecapeptide BPC 157, Robert's stomach cytoprotection/adaptive cytoprotection/organoprotection, and Selye's stress coping response. Current Pharmaceutical Design. 2018;24(18):1994–2003.
- Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066–19077.
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy. 2012;12(1):37–51.
- Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB Journal. 2010;24(7):2144–2151.
- Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science Polymer Edition. 2008;19(8):969–988.
JSON-LD Article Schema
This content is produced by the Palmetto Peptides Research Team for educational and informational purposes only. GHK-Cu, BPC-157, and TB-500 are research compounds intended for in vitro and preclinical laboratory use by qualified researchers only. None are approved by the FDA for human or veterinary use. Nothing in this guide constitutes medical advice or a recommendation for human use.
Author: Palmetto Peptides Research Team
The Glow Stack and GHK-Cu are available from Palmetto Peptides.